Formulary Search Results for: DABRAFENIB
8.1.5 Other antineoplastic drugs - View Category
Total Formulary
DABRAFENIB (capsules)
Restrictions:
Restricted to specialist use in accordance with regional protocols for the following indications:
- Unresectable or metastatic BRAF V600 mutation-positive metastatic melanoma who have received no prior therapy (click here for protocol)
- In combination with trametinib for the adjuvant treatment of adults with stage III melanoma with a BRAF V600 mutation following complete resection (click here for local protocol)
- In combination with trametinib for the treatment of adults with locally advanced or metastatic anaplastic thyroid cancer with evidence of a BRAF V600E mutation and with no satisfactory locoregional treatment options (NCMAG 107, regional protocol under development).
Prescribing Notes:
The following indications are not recommended for use by the SMC and are non-Formulary:
- In combination with trametinib for the treatment of adults with advanced non-small cell lung cancer with BRAF V600 mutation.